Skip to main content

Research Repository

Advanced Search

All Outputs (2)

Identification of the Antigens Recognised by Colorectal Cancer Patients Using Sera from Patients Who Exhibit a Crohn’s-like Lymphoid Reaction (2022)
Journal Article
Boncheva, V. B., Linnebacher, M., Kdimati, S., Draper, H., Orchard, L., Mills, K. I., …Guinn, B. A. (2022). Identification of the Antigens Recognised by Colorectal Cancer Patients Using Sera from Patients Who Exhibit a Crohn’s-like Lymphoid Reaction. Biomolecules, 12(8), 1058. https://doi.org/10.3390/biom12081058

A Crohn’s-like lymphoid reaction (CLR) is observed in about 15% of colorectal cancer (CRC) patients and is associated with favourable outcomes. To identify the immune targets recognised by CRC CLR patient sera, we immunoscreened a testes cDNA library... Read More about Identification of the Antigens Recognised by Colorectal Cancer Patients Using Sera from Patients Who Exhibit a Crohn’s-like Lymphoid Reaction.

Oral tolerance to cancer can be abrogated by T regulatory cell inhibition (2014)
Journal Article
Whelan, M. C., Casey, G., Larkin, J. O., Guinn, B. A., O'Sullivan, G. C., & Tangney, M. (2014). Oral tolerance to cancer can be abrogated by T regulatory cell inhibition. PLoS ONE, 9(5), Article e97602. https://doi.org/10.1371/journal.pone.0097602

Oral administration of tumour cells induces an immune hypo-responsiveness known as oral tolerance. We have previously shown that oral tolerance to a cancer is tumour antigen specific, non-cross-reactive and confers a tumour growth advantage. We inves... Read More about Oral tolerance to cancer can be abrogated by T regulatory cell inhibition.